Early response assessment to guide management of Methicillin-Resistant Staphylococcus aureus bloodstream infections with vancomycin therapy

Clinical Therapeutics

Volumn 35, Issue 7, 2013, Pages 995-1004

  Joo, Julianne ^a,b,c   Yamaki, Jason ^a   Lou, Mimi ^a   Hshieh, Shenche ^a   Chu, Tony ^a   Shriner, Kimberly A ^b   Wong Beringer, Annie ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

^c OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

MRSA; MRSA bloodstream infection; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; APACHE; ARTICLE; BACTEREMIA; BACTERIAL CHROMOSOME; BLOODSTREAM INFECTION; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

MRSA; MRSA BLOODSTREAM INFECTION; VANCOMYCIN;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84880430952     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.018     Document Type: Article

References (17)

1. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
2. Howden B.P., Davies J.K., Johnson P.D., et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23:99-139.
3. Boucher H., Miller L.G., Razonable R.R. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010, 51(suppl 2):S183-S197.
4. van Hal S.J., Lodise T.P., Paterson D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012, 54:755-771.
5. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.
6. Rybak M.J., Lomaestro B.M., Rotscahfer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
7. Wong-Beringer A., Joo J., Tse E., et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2010, 37:95-101.
8. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
9. Lodise T.P., Patel N., Lomaestro B.M., et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009, 49:507-514.
10. Moore C.L., Osaki-Kiyan P., Haque N.Z., et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012, 54:51-58.
11. Bonnstetter K.K., Wolter D.J., Tenover F.C., et al. Rapid multiplex PCR assay for identification of USA 300 community-associated methicillin-resistant Staphylococcus aureus isolates. J Clin Microbiol 2007, 45:141-146.
12. Boye K., Bartels M.D., Andersen I.S., et al. A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I-V. Clin Microbiol Infect 2007, 13:725-727.
13. Fowler V.G., Justice A., Moore C., et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005, 40:695-703.
14. Levine D.P., Fromm B.S., Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991, 115:674-680.
15. Moise P.A., Forrest A., Bayer A.S., et al. Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J Infect Dis 2010, 201:233-240.
16. Cui L., Neoh H.M., Shoji M., et al. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:1231-1234.
17. Neoh H.M., Cui L., Yuzawa H., et al. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 2008, 52:45-53.